## Abstract With the aid of an assay measuring complement dependent cytotoxicity mediated by syngeneic antibodies, we performed a serological analysis of surface antigens of a polyoma‐virus‐induced murine tumor (SEYF‐a). __In vivo__ propagated SEYF‐a ascites tumor cells expressed a specific membran
Compared action of a polyoma-virus-specific inhibitor on the formation of polyoma capsid antigen and of polyoma tumor antigen
✍ Scribed by Georges Meyer; Robert Cramer; Hiroshi Yoshikura
- Publisher
- John Wiley and Sons
- Year
- 1972
- Tongue
- French
- Weight
- 417 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A protein factor which can be extracted from polyoma‐virus‐transformed BHK 21 cells is shown not to inhibit a virus‐coded early function (tumour antigen formation), whereas it inhibits the formation of the virus capsid antigen.
📜 SIMILAR VOLUMES
Mice and rats could be immunized against the polyoma-virus-induced tumor-specific transplantation antigen (TSTA) by repeated inoculation of frozen or irradiated cells of an MT-cDNA-transformed rat cell line (2.8) that contains only the polyoma middle T-antigen, or by cells that carried a host range
We have examined the effect of polyoma virus infection of primary mouse embryo cells on the tyrosyl kinase activity associated with the cellular src gene product, pp60c-src. The results of our studies demonstrate that infection of mouse cells with wild-type polyoma virus or viral mutants capable of
Two polyoma-TSTA-negative variants were selected independently from a polyoma fibrosarcomdMoloney lymphoma somatic hybrid, by repeated passages in polyoma-virus-preimmunized mice. One of the variants had lost all its polyoma DNA, while the other only retained a deleted piece of its integrated polyom
## Abstract We previously reported that inoculation of rats with live vaccinia virus (VV) recombinants VVpyMT, VVpyLT expressing either the middle‐T (MT) or large‐T (LT) proteins of polyomavirus (PyV) can elicit immunity to challenge with syngeneic PyV‐tumor cells. We now report the results of cros